These insights raise the possibility that multiple SMAD2/3 pathway–activating ligands drive pathologic vascular remodeling in PAH, but their identities, respective contributions, and cellular sites of action remain incompletely characterized. This evidence concerns the gene SMAD2 and pulmonary arterial hypertension.